Biotech Values

[DewDiligence]

Baxter’s biennial Investor Day presentation was held on on 9/16/09. The PR announcing the presentation included these notable excerpts (see the end of this post for the presentation slides):

http://finance.yahoo.com/news/Baxter-Hosts-2009-Investor-bw-3360789694.html?x=0&.v=1

Over its five-year long-range plan period , Baxter expects to increase sales approximately 7 to 8 percent (excluding the impact of foreign currency), grow earnings per share in the 11 to 13 percent range, and generate strong annual cash flow of approximately $4 billion by the year 2014. The company also plans to continue focusing on innovation and expanding its robust pipeline by increasing investments in R&D at a compounded annual rate of at least 8 to 10 percent.

Over the last 12 months, Baxter has initiated 14 Phase III clinical trials, and is advancing numerous earlier stage clinical trials of therapies that have the potential to profoundly impact the treatment and delivery of care for chronic diseases like Alzheimer’s, kidney failure, cardiovascular, diabetes, thrombotic thrombocytopenic purpura, multifocal motor neuropathy, as well as public health threats like pandemic and seasonal influenza.

The presentation slides are in seven separate pdf files at: http://investor.baxter.com/phoenix.zhtml?c=86121&p=irol-EventDetails&EventId=2026093 .